Patients
tumor, toxicity, AITL, PTCL-NOS, ALK-ALCL, peripheral T-cell lymphoma, killer/T-cell lymphoma, ENKTL
DISEASE PROGRESSION, TUMOR, PERIPHERAL T-CELL LYMPHOMA, DISEASE, ANAPLASTIC LARGE CELL LYMPHOMA, ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Twenty patients were enrolled and received study medications in the study. A total of 15 patients received 500 mg of apatinib, and five patients received 250 mg. Six patients had early discontinuation without tumor response evaluation (one patient was due to toxicity after only one dose of camrelizumab; two patients withdrew consent, and three patients withdrew due to disease progression but not hyperprogression). At the cutoff date of March 4, 2022, the median follow-up was 27.2 months (range: 0.5 to 39.9 months), and three patients remained on treatment (Patient flowchart.The median age of all patients was 52.5 years (range 22 to 66), and 13 patients (65%) were male. Seventeen (85%) had diagnosed stage III–IV disease. The most common subtypes were ENKTL (35%) and PTCL-NOS (30%). Patients were heavily pretreated before enrollment, with a median prior treatment line of 3 (range: 1-6). Most patients were assessed as being transplant ineligible because of chemotherapy resistance or rapid progression. Among the patients, 15 had refractory disease while five had relapsed disease. Two of seven patients with ENKTL had a PINK score of ≥2, while ten of 13 patients with other PTCL subtypes had an international prognostic index (IPI) score of ≥2. All seven patients with ENKTL had previously received asparaginase-based chemotherapy, and all patients with other subtypes of PTCL had received anthracycline-based chemotherapy. Eleven (55%) patients had previously received chidamide, and four (20%) patients had received autologous HSCT. The detailed baseline characteristics are shown in Baseline characteristics of patients.ENKTL, extra nodal natural killer/T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK-ALCL, ALK negative anaplastic large cell lymphoma; IPI, international prognostic index; HSCT, hematopoietic stem cell transplant.